zepbound Logo (EUIPO, 08/16/2022)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark zepbound was filed as Figurative mark on 08/16/2022 at the European Union Intellectual Property Office.
It was registered as a trademark on 02/15/2023.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Several triangles, juxtaposed, joined or intersecting #Triangles with dark surfaces or parts of surfaces
| Trademark form | Figurative mark |
| File reference | 018748013 |
| Application date | August 16, 2022 |
| Publication date | November 8, 2022 |
| Entry date | February 15, 2023 |
| Expiration date | August 16, 2032 |
Trademark owner
Lilly Corporate Center
46285 Indianapolis,
US
46285 Indianapolis,
US
Trademark representatives
Widenmayerstr. 10
80538 München
DE
goods and services
5
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, and Crohn's disease; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, and mental disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; pharmaceutical preparations
ID: 11018748013